deltatrials
Completed PHASE1 NCT00666926

Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-00562271 In Patients With Advanced Non-Hematologic Malignancies

Sponsor: Verastem, Inc.

Conditions Head and Neck Neoplasm Pancreatic Neoplasm Prostatic Neoplasm
Interventions PF00562271
Updated 7 times since 2017 Last updated: Mar 14, 2013 Started: Dec 31, 2005 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

Listed as NCT00666926, this PHASE1 trial focuses on Head and Neck Neoplasm and Pancreatic Neoplasm and remains completed. Sponsored by Verastem, Inc., it has been updated 7 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Verastem, Inc.
Data source: Verastem, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Aurora, United States
  • • East Melbourne, Australia
  • • Nashville, United States
  • • Toronto, Canada